"You'll just gain it all back." It's the dismissal that follows almost every conversation about GLP-1 medications — usually delivered by someone who's never read the STEP extension data and conflates "medication requires ongoing use" with "medication doesn't work."
Let's look at what the data actually shows, and then let's talk about what it means.
The STEP 1 Extension: The Most-Cited Regain Data
In the STEP 1 extension study, patients who lost an average of ~17% body weight on semaglutide 2.4 mg over 68 weeks were switched to placebo. Over the following year, they regained approximately two-thirds of the weight they had lost — stabilizing at roughly 5–6% below their original starting weight.
This is the number that gets weaponized. But it requires context.
The Context Nobody Mentions
Blood pressure medication works the same way. If you stop taking lisinopril, your blood pressure goes back up. Nobody calls hypertension treatment a "failure" because it requires ongoing medication. Obesity is a chronic disease driven by hormonal and neurological factors. GLP-1 medications treat those factors. Stopping treatment means stopping treatment — the underlying condition doesn't vanish because you felt better for a while.
Patients who continued medication maintained their weight loss. The STEP 5 trial — the longest randomized controlled data available — showed that patients who remained on semaglutide 2.4 mg for two full years maintained approximately 15% weight loss at 104 weeks, with the weight-loss curve still slightly declining at study end. Continued treatment works. The "regain" data is about what happens when you stop, not about what happens when you continue.
Residual benefit persists even after stopping. The STEP 1 extension patients didn't regain everything. At one year off the drug, they still retained approximately one-third of their weight loss — translating to approximately 5–6% body weight reduction from baseline. That level of sustained weight loss is associated with clinically meaningful improvements in blood pressure, blood glucose, and cardiovascular risk markers.
"You'll gain it all back" is misleading in three ways: it implies you regain 100% (you don't — one-third is retained even off-drug), it ignores that most patients don't stop (ongoing treatment maintains results), and it applies a standard to obesity medication that we don't apply to any other chronic disease treatment. The honest framing: GLP-1s are most effective as ongoing therapy, and stopping them results in partial regain — just like stopping any chronic disease medication results in return of the underlying condition.
If you're concerned about long-term use, ask your provider about dose optimization (some patients maintain at lower doses), whether lifestyle modifications can partially replace medication over time, and what a gradual taper looks like versus abrupt discontinuation. The evidence on controlled tapering is limited but growing, and it may offer a middle path between "full dose forever" and "cold turkey."
Sema $99/mo, tirz $133/mo at any dose. LegitScript certified, 503A+503B pharmacies. Free consult, free shipping, no membership. Also NAD+ and sermorelin. Code x7X72r saves $25.
$99/month at every dose — verified flat. LegitScript, FSA/HSA. No price jumps at maintenance.
Compounded sema $125/mo, tirz $199/mo. Brand-name Mounjaro/Zepbound available. Code Bilt35 = 35% off first order.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All medications require evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved. Individual results vary.